The DOI matches its Crossref record, with a small difference in title or year; 7 of the 7 references it cites were found in a registry or an index.
Finerenone and Kidney Outcomes in Patients With Heart Failure
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetes, GLP-1 receptor agonists have been reported to diminish eGFR during short-term treatment, but to improve glomerular function during long-term treatment,34,87,88 a biphasic effect that is similar to that observed with mineralocorticoid receptor antagonists and SGLT2 inhibitors.79,86”
From Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [86]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citationFinerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407107 · Cited by 893
Self-citationLevey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Research works printed but not linked: 17
- Damman, 2014, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, Eur Heart J, 35, 455, 10.1093/eurheartj/eht386 · DOI
- Ostrominski, 2024, Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction a trial-level analysis, J Am Coll Cardiol, 84, 223, 10.1016/j.jacc.2024.05.005 · DOI
- Jackson, 2009, Albuminuria in chronic heart failure: prevalence and prognostic importance, Lancet, 374, 543, 10.1016/S0140-6736(09)61378-7 · DOI
- Selvaraj, 2018, Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.118.005288 · DOI · Paper page
- Causland, 2020, Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction, Circulation, 142, 1236, 10.1161/CIRCULATIONAHA.120.047643 · DOI
- Causland, 2023, Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction, JAMA Cardiol, 8, 56, 10.1001/jamacardio.2022.4210 · DOI
- Butt, 2024, Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: comprehensive individual participant-level analysis of 6 randomized clinical trials, Circulation, 150, 1858, 10.1161/CIRCULATIONAHA.124.071110 · DOI
- Vaduganathan, 2024, Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial, Eur J Hear Fail, 26, 1324, 10.1002/ejhf.3253 · DOI
- Agarwal, 2023, Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis, Ann Intern Med, 176, 1606, 10.7326/M23-1023 · DOI · Paper page
- Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081 · DOI · Paper page
- Beldhuis, 2021, Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function, J Am Coll Cardiol, 77, 1211, 10.1016/j.jacc.2020.12.057 · DOI
- Vaduganathan, 2022, Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure, Eur J Heart Fail, 24, 1586, 10.1002/ejhf.2635 · DOI
- Vaduganathan, 2024, Why has it been challenging to modify kidney disease progression in patients with heart failure?, J Am Coll Cardiol, 84, 2241, 10.1016/j.jacc.2024.08.034 · DOI
- Vaduganathan, 2024, Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes, Nat Med, 30, 3758, 10.1038/s41591-024-03264-4 · DOI · Paper page
- Neuen, 2024, Timing of cardio-kidney protection with SGLT2 inhibitors: insights from 4 large-scale placebo-controlled outcome trials, Circulation, 150, 343, 10.1161/CIRCULATIONAHA.124.069382 · DOI
- Sharma, 2023, Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial, Eur J Hear Fail, 25, 1337, 10.1002/ejhf.2857 · DOI · Paper page
- Pitt, 2013, Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial, Eur Heart J, 34, 2453, 10.1093/eurheartj/eht187 · DOI
Cited by
Sorted by citations
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Metadata
- Authors
- Mc Causland, F. R., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Brinker, M., Perkins, R., Scheerer, M. F., Schloemer, P., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Pitt, B., McMurray, J. J. V., & Solomon, S. D.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 85
- Issue
- 2
- Pages
- 159-168
- ISSN
- 0735-1097
- Cited by
- 86
- References
- 7
- Language
- en
- Licence
- Funders
- Bayer AG
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
